CRISPR Therapeutics (CRSP)
(Delayed Data from NSDQ)
$45.58 USD
-1.40 (-2.98%)
Updated Oct 1, 2024 04:00 PM ET
Pre-Market: $45.25 -0.33 (-0.72%) 8:10 AM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Company Summary
Founded in 2013, Switzerland-based CRISPR Therapeutics AG is a leading gene editing company focused on developing CRISPR/Cas9-based therapeutics. The company is rapidly leveraging its CRISPR/Cas9 gene-editing platform to make therapies for the treatment of hemoglobinopathies, cancer, diabetes and other diseases. The company has traded publicly since October 2016.
CRISPR Therapeutics achieved a milestone in November 2023 when it received the first-ever authorization/approval for a CRISPR/Cas9 gene-edited therapy. The therapy, marketed under the trade name Casgevy (exa-cel), secured its first-ever approval/authorization in the United Kingdom for treating two debilitating blood disorders, ...
Company Summary
Founded in 2013, Switzerland-based CRISPR Therapeutics AG is a leading gene editing company focused on developing CRISPR/Cas9-based therapeutics. The company is rapidly leveraging its CRISPR/Cas9 gene-editing platform to make therapies for the treatment of hemoglobinopathies, cancer, diabetes and other diseases. The company has traded publicly since October 2016.
CRISPR Therapeutics achieved a milestone in November 2023 when it received the first-ever authorization/approval for a CRISPR/Cas9 gene-edited therapy. The therapy, marketed under the trade name Casgevy (exa-cel), secured its first-ever approval/authorization in the United Kingdom for treating two debilitating blood disorders, sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).
While the FDA approved Casgevy for SCD indication in December 2023, the therapy received label expansion in TDT indication in January 2024. In February 2024, the European Commission granted conditional marketing authorization to Casgevy to treat SCD and TDT.
Following the above regulatory approvals, Casgevy is the first approved/authorized gene therapy based on CRISPR technology. It is also the first marketed product in CRISPR Therapeutics’ portfolio. Casgevy has been developed as part of a co-development and co-commercialization agreement with Vertex Pharmaceuticals.
CRISPR Therapeutics is also developing two gene-edited allogeneic cell therapy programs, next-generation chimeric antigen receptor T cell (CAR-T) candidates, CTX112 and CTX131, for hematological and solid tumor cancers and autoimmune indications.
In 2023, CRISPR Therapeutics generated $371.2 million as total revenues (generated entirely from collaboration revenues), reflecting a substantial rise from the previous year’s $1.2 million.
General Information
CRISPR Therapeutics AG
BAARERSTRASSE 14
ZUG, V8 CH-6300
Phone: 41-41-561-3277
Fax: NA
Email: susan.kim@crisprtx.com
Industry | Medical - Biomedical and Genetics |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 9/30/2024 |
Exp Earnings Date | 11/4/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | -1.45 |
Current Year EPS Consensus Estimate | -5.58 |
Estimated Long-Term EPS Growth Rate | NA |
Exp Earnings Date | 11/4/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 46.98 |
52 Week High | 91.10 |
52 Week Low | 37.55 |
Beta | 1.68 |
20 Day Moving Average | 1,060,941.25 |
Target Price Consensus | 82.25 |
4 Week | 0.13 |
12 Week | -17.17 |
YTD | -27.19 |
4 Week | -3.02 |
12 Week | -19.08 |
YTD | -39.16 |
Shares Outstanding (millions) | 85.05 |
Market Capitalization (millions) | 3,876.37 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | NA |
Change in Payout Ratio | NA |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | NA |
Trailing 12 Months | NA |
PEG Ratio | NA |
vs. Previous Year | -52.04% |
vs. Previous Quarter | -4.20% |
vs. Previous Year | -99.26% |
vs. Previous Quarter | 2.58% |
Price/Book | 1.96 |
Price/Cash Flow | NA |
Price / Sales | NA |
9/30/24 | Pending Next EPS Report |
6/30/24 | -13.85 |
3/31/24 | -11.56 |
9/30/24 | Pending Next EPS Report |
6/30/24 | -11.69 |
3/31/24 | -9.70 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 15.73 |
3/31/24 | 17.81 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 15.73 |
3/31/24 | 17.81 |
9/30/24 | NA |
6/30/24 | NA |
3/31/24 | NA |
9/30/24 | NA |
6/30/24 | NA |
3/31/24 | NA |
9/30/24 | Pending Next EPS Report |
6/30/24 | -130.12 |
3/31/24 | -79.07 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 23.29 |
3/31/24 | 24.55 |
9/30/24 | NA |
6/30/24 | NA |
3/31/24 | NA |
9/30/24 | Pending Next EPS Report |
6/30/24 | 0.00 |
3/31/24 | 0.00 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 0.00 |
3/31/24 | 0.00 |